Vancouver, British Columbia / TheNewswire / November 15, 2016 – Vodis Pharmaceuticals Inc. (CSE: VP / FSE: 1JV) ("Vodis" or the "Company") announces the appointment of Mr. Derek Good to the Board of Directors.

 

Vodis would like to announce the appointment of Derek Good to the Board of Directors.  Mr. Good is a co-founder of Vodis Pharmaceuticals and through numerous investments in private placements, he has become the largest shareholder in the Company.  Mr. Good has also been a significant lender to the company and recently converted the majority of his loans into the Company’s common shares (see press release dated Oct 14, 2016).

“I have been a backer of Vodis since its inception and will now add an increased level of support from the Board level.  The opportunity we have at this moment in time is unparalleled to anything I have seen before.  We have had some volatility but our focus and determination has never strayed.  I firmly believe the participants at the helm of the Company today will be rewarded for their perseverance and vision.”

Mr. Good had the vision and foresight to guide the company into Washington State and has become a huge advocate for the opportunities Washington presents.  Mr. Good has been a successful entrepreneur and venture capitalist, having invested in numerous companies in the past few years, Vodis will now be his main focus.  

Prior to Vodis, Mr. Good co-founded and was an owner/operator of a multi-faceted private label food production company with a 3,000 sq.ft. commercial kitchen.  He has more than a decade of extensive experience in food production, food safety and development and implementation of Standard Operating Procedures for production facilities that are very similar to the marijuana business.  Mr. Good took the Company from concept to sales exceeding $1,500,000 before successfully exiting by selling the business to multiple companies as well as divesting the real estate.

Please feel free to follow Mr. Good on Twitter at @derekgoodVP.

 

About Vodis Pharmaceuticals Inc.

 

Vodis is one of North America’s foremost brand names in the medical and recreational marijuana business with operations in both the United States and Canada. Its master grow teams have consistently won or placed at each competition they have entered with their “VIP” brand. The Company, with facilities in BC and Washington State, is also actively looking into expansion opportunities in other countries and states in the United States.

 

While Vodis Pharmaceuticals and its subsidiaries cannot have any interest whatsoever in any proceeds as a result of production, processing or retail activities in the United States, it can license its brand, production and consulting services to approved Washington State license holders to ensure that all products produced under the Vodis Pharmaceuticals program and/or associated under the VIP brand meet or exceed the Vodis brand quality standards.

For further information, please contact:

Ivan Miliovski

Chief Executive Officer

Vodis Innovative Pharmaceuticals Inc.

8788 River Rd, Delta, V4G 1B4, Canada

Cell: 778-242-9677

Website: www.vodis.ca

 

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

 

Forward-Looking Information:

 

Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “expects” or “it is expected”, or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including: the use of proceeds of this financing. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update any forward-looking statements or forward-looking information that is incorporated by reference herein, except as required by applicable securities laws.